SCHEMBL1760110

SCHEMBL1760110

CC(C)(C)OC(=O)N(N)c1cccnc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.43
NAMPT P43490 2/20 0.41
GPR119 Q8TDV5 2/20 0.39
NOTUM Q6P988 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 4/20 0.38
CYP1A2 P05177 2/20 0.38
LMNA P02545 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HTT P42858 1/20 0.38
F7 P08709 1/20 0.38
F3 P13726 1/20 0.38
SARM1 Q6SZW1 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
SIRT6 Q8N6T7 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
SIRT3 Q9NTG7 1/20 0.38
SIRT5 Q9NXA8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2133772 0.85 MKNK1 (0.48) GPR119ALDH1A1CYP3A4CYP1A2CYP11B1
SCHEMBL9571667 0.84 RAB9A (0.45) RAB9ANAMPTGPR119NOTUMALDH1A1
SCHEMBL479924 0.83 NOTUM (0.48) RAB9ANAMPTGPR119NOTUMALDH1A1
SCHEMBL31554105 0.83 NOTUM (0.48) RAB9ANAMPTGPR119NOTUMALDH1A1
SCHEMBL28888014 0.82 RAB9A (0.43) RAB9ANAMPTGPR119NOTUMALDH1A1
SCHEMBL15948302 0.81 F2 (0.38) GPR119LMNACYP17A1CYP19A1
SCHEMBL29156727 0.81 GPR119 (0.33) GPR119
SCHEMBL9571669 0.81 RAB9A (0.42) RAB9ANAMPTGPR119NOTUMALDH1A1
SCHEMBL1529415 0.81 PTGIR (0.49) RAB9ANAMPTGPR119NOTUMTDP1
SCHEMBL2354804 0.80 L3MBTL1 (0.43) RAB9AALDH1A1CYP3A4TDP1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011057993-A1 INDAZOLONE DERIVATIVES AS GLYCOGEN SYNTHASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-05-19 WO disclosed
US-20110112147-A1 INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS BOLIN DAVID ROBERT 2011-05-12 US disclosed
US-20110112147-A1 INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS BOLIN DAVID ROBERT 2011-05-12 US disclosed
US-20110112147-A1 INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS BOLIN DAVID ROBERT 2011-05-12 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112147-A1 INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS GYS2, GYS1, PYGL RAB9A 3587/4885NAMPT 1069/4885GPR119 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.